ArticleAmerican journal of translational research2026
Well-established efficacy of camrelizumab combined with radiofrequency ablation in cirrhotic patients with hepatic cancer.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze the efficacy of camrelizumab combined with radiofrequency ablation (RFA) in cirrhotic patients with hepatic cancer.
methodsA total of 89 cirrhotic patients with hepatic cancer were enrolled. The control group (n = 40) received RFA alone, and the research group (n = 49) received camrelizumab combined with RFA. Their clinical data were compared, including efficacy, liver function indicators, inflammatory markers, serum tumor markers, humoral immune function parameters, and incidence of adverse reactions. Factors influencing the efficacy and safety of treatment in these patients were also explored.
resultsThe research group demonstrated a significantly higher total effective rate than the control group (89.80% vs. 70.00%, P = 0.018). Post-treatment, the research group had significantly lower liver function indicators (serum total bilirubin (TBIL), alanine aminotransferase (ALT), aspartate aminotransferase (AST)), inflammatory markers (Interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), high-sensitivity c-reactive protein (hs-CRP)), and serum tumor markers (alpha-fetoprotein (AFP), liver cancer paternally expressed gene 10 (PEG10), and carbohydrate antigen 199 (CA199)) (all P<0.05). In contrast, the research group had significantly higher humoral immune function parameters (immunoglobulin A (IgA), IgG, IgM), with statistically significant differences (all P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P = 0.864). Finally, Child-Pugh Class B, tumor size ≥4 cm, AST ≥77 U/L, AFP ≥420 μg/L, and treatment with RFA alone were found to be associated with an increased risk of treatment failure or adverse events (all P<0.05).
conclusionThe combination of camrelizumab and RFA demonstrates superior efficacy in the treatment of cirrhotic patients with hepatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.